Gloria H. Su, PhD

Profile Headshot

Overview

Academic Appointments

  • Professor of Pathology and Cell Biology (in Otolaryngology/Head and Neck Surgery and in the Herbert Irving Comprehensive Cancer Center)

Credentials & Experience

Education & Training

  • BA, Biological Sciences, Northwestern University
  • PhD, Immunology, University of Chicago

Honors & Awards

  • 2015      Distinguished Achievement Award from Shanghai Tongji University East Hospital for exceptional contribution to pancreatic cancer research and clinical management

  • 2014      Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research

Research

Dr. Gloria Su and her laboratory study the molecular genetics of head and neck squamous cell carcinoma (HNSCC) and pancreatic ductal adenocarcinoma, as well as mouse modeling needed for both cancer types. HNSCC and pancreatic ductal adenocarcinoma are both results of accumulated genetic alterations. Both cancer types share some common oncogenes and tumor-suppressor genes (e.g. p16 and p53), but each has its unique targeted mutations (e.g. Cyclin D1 for HNSCC and K-ras for pancreatic cancer). We continue to compare and contrast the molecular genetic profiles of these two cancer types using both broad genome-scanning approach and candidate-gene approach. By establishing the cancer genetic profiles, we hope to reveal new prognostic markers, discover tumor marker for early detection analysis, and develop chemopreventive and therapeutic treatments that target tumor-specific pathways.

Dr. Su’s laboratory has developed multiple genetically-engineered mouse models that recapitulate human pancreatic cancer at both genetic and histologic levels. Using these genetically-engineered mouse models, Dr. Su’s team is interrogating the biology of tumor development, progression, and metastasis. Notably, her team has reported that the loss of the wild-type KRAS is associated with pancreatic cancer metastasis in mice and in humans. They have also demonstrated that the inactivation of different tumor-suppressor genes following Kras activation may influence the dichotomy of PanIN and IPMN (pancreatic precancerous lesions) development and progression. Specifically, the inactivation of the activin signaling preferentially promotes the development of IPMN. In addition to mouse modeling, Dr. Su and her team have contributed to our understanding of the cancer genetics of human IPMN and recently shown that the dysregulation of the PI3K-PTEN signaling pathway is associated with poor prognosis among IPMN patients.

Research Interests

  • Genetic profiling of human pancreatic cancer and head and neck cancer, and mouse modeling for both cancer types

Grants

THE DEVELOPMENT AND PROGRESSION OF IPMN TO PDA IN THE CONTEXT OF INACTIVATED ACTIVIN SIGNALING (Federal Gov)

Mar 15 2017 - Feb 28 2022

GENOMICS AND MECHANISMS OF ESOPHAGEAL CARCINOGENESIS (Federal Gov)

Sep 21 2016 - Aug 31 2021

THE ROLE OF WILD-TYPE KRAS IN THE CONTEXT OF TUMOR PROGRESSION AND METASTASIS (Federal Gov)

May 1 2015 - Apr 30 2020

PATHWAY-SPECIFIC EXOSOMAL PROFILING IN MURINE MODELS OF HEAD AND NECK SQUAMOUS CELL CARCINOMA (Private)

Apr 1 2016 - Mar 31 2017

MOUSE MODEL FOR HUMAN PANCREATIC DUCTAL ADENOCARCINOMA (Federal Gov)

Sep 1 2004 - Mar 31 2017

PREDICTING PANCREATIC CANCER RESPONSES IN A PARP INHIBITOR-BASED CINICAL TRIAL (Federal Gov)

Sep 30 2009 - Aug 31 2013

NOTCH DECOY TARGETING THE NOTCH SIGNALING PATHWAY IN PANCREA TIC CANCER (Private)

Jul 1 2010 - Jun 30 2012

THE TUMOR-SUPPRESSIVE ROLE OF ALK4/ACVR1B IN PANCREATIC TUMO RIGENESIS (Federal Gov)

Jul 1 2008 - Jun 30 2011

Selected Publications

  • D. J. Lenshow, G. H. Su, L. A. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gray, J. Miller, J. A. Bluestone.  Expression and functional significance of an additional ligand for CTLA-4.  Proc. Natl. Acad. Sci. USA 1993; 90:11054-11058
  • G. H. Su, H. S. Ip, B. S. Cobb, M. Lu, H. Chen, M. C. Simon.  The Ets protein Spi-B is expressed exclusively in B cells and T cells during development. Journal of  Experimental Medicine 1996; 184:203-214
  • G. H. Su, H-M Chen, N. Muthusamy, L. A. Garrett-Sinha, D. Baunoch, D. G. Tenen, M. C. Simon.  Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B.  The EMBO Journal 1997; 16:7118-7129
  • G. H. Su, W. Hilgers, M. C. Sheker, D. J. Tang, C. J. Yeo, R. H. Hruban, S. E. Kern.  Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene.  Cancer Research 1998; 58:2339-2342
  • G. H. Su, R. H. Hruban, R. K. Bansal, G. S. Bova, D. J. Tang, M. C. Sheker, A. M. Westerman, M. M. Entius, M. Goggins, C. J. Yeo, S. E. Kern.  Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.  American Journal of Pathology 1999; 154:1835-1840
  • G. H. Su, T. A. Sohn, B. Ryu, S. E. Kern.  A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library.  Cancer Research 2000, 60:3137-42. 
  • G. H. Su, R. Bansal, K. M. Murphy, E. Montgomery, C. J. Yeo, R. H. Hruban, S. E. Kern. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.  Proc. Natl. Acad. Sci. USA 2001, 98: 3254-7.
  • G. H. Su, J. J. Song, E. A. Repasky, M. Schutte, S. E. Kern.  Mutation fate of MAP2K4/MKK4 in breast carcinoma.  Human Mutation 2002, 19:81.
  • F. Sahin, A. Maitra, P. Argani, N. Sato, N. Maehara, E. Montgomery, M. Goggins, R. H. Hruban, G. H. Su.  Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms.  Modern Pathology 2003, 16:686-91
  • F. Sahin, W. Qiu, R. E. Wilentz, C. A. Iacobuzio-Donahue, A. Grosmark, G. H. Su.  RPL38, FOSL1, and UPP1 are predominately expressed in the pancreatic ductal epithelium.  Pancreas 2005, 30:158-67. 
  • W. Qiu, F. Schönleben, H. M. Thaker, M. Goggins, G. H. Su.  A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma.  Oncogene 2006, 25:2937-42.
  • W. Qiu, , X. Li, D. J. Ho, L. G. Close, S. Manolidis, B. P. Bennett, G. H. Su.  PIK3CA mutations in head and neck squamous cell carcinoma.  Clinical Cancer Research 2006, 12:1441-6. 
  • F. Schönleben, W. Qiu, N. T. Ciau, D. J. Ho, X. Li, J. D. Allendorf, H. E. Remotti, G. H. Su.  PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Clinical Cancer Research 2006, 12:3851-5. 
  • W. Qiu, F. Schönleben, X. Li, G. H. Su.  Disruption of Transforming Growth Factor β–Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.  Cancer Letter 2007 Jan 8; 245(1-2):163-70. Epub 2006 Feb 14.
  • F. Schönleben, W. Qiu, K. C. Bruckman, N. T. Ciau, X. Li, M. H. Lauerman, H. Frucht, J. A. Chabot, J. D. Allendorf, H. E. Remotti, G. H. Su.  BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Letters 2007 May 8; 249(2):242-8. Epub 2006 Nov 9.
  • W. Qiu, G.-X. Tong, S. Manolidis, L. G. Close, A. M. Assaad, G. H. Su.  Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.  International Journal of Cancer 2008, 122:1189-94 (Epub 2007 Nov 7).
  • F. Schönleben, W. Qiu, H. E. Remotti, W. Hohenberger, G. H. Su.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.   Langenbecks Arch Surg 2008, 393(3):289-96
  • F. Schönleben, J. D. Allendorf, W. Qiu, X. Li, D. J. Ho, N. T. Ciau, R. L. Fine, J. A. Chabot, H. E. Remotti, G. H. Su.  Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.  Pancreas 2008, 36: 168-72.
  • V. Vinarsky, R. L. Fine, A. Assaad, Y. Qian, J. A. Chabot, G. H. Su, H. Frucht.  Head and neck squamous cell carcinoma in FAMMM syndrome. Head and Neck 2009, 31(11):1524-27.
  • F. Schönleben, W. Qiu, J. D. Allendorf, J. A. Chabot, H. E. Remotti, G. H. Su.  Molecular analysis of PIK3CA, BRAF, and RAS- oncogenes in periampullary and ampullary adenomas and carcinomas.  Journal of Gastrointestinal Surgery 2009, 13(8);1510-6 (Epub 2009 May 14). 
  • K. C. Bruckman, F. Schönleben, W. Qiu, V. L. Woo, G. H. Su. Mutational frequency of the PIK3CA, KRAS, and BRAF genes in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2010, 110(5):632-7 (Epub 2010 Sept 1).
  • D. J. Lee, F. Schönleben, V. E. Banuchi, W. Qiu, L. G. Close, A. M. Assaad, G. H. Su.  Multiple tumor-suppressor genes on chromosome 3p contribute to head and neck squamous cell carcinoma tumorigenesis. Cancer Biology & Therapy 2010, 10(7):1-5.
  • W. Qiu, X. Li, H. Tang, A. S. Huang, A. A. Panteleyev, D. M. Owens, G. H. Su.  Conditional activin reporter type IB (Acvr1b) knockout mice revealed hair loss abnormality.  Journal of Investigative Dermatology 2011, 131:1067-76 (Epub Dec 2010). 
  • J. DiNorcia, M. K. Lee, D. N. Moroziewicz, M. D. Winner, P. Suman, F. Bao, H. E. Remotti, Y. S. Zou, S. F. Yan, W. Qiu, G. H. Su, A. M. Schmidt, J. D. Allendorf. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a mouse model of pancreatic cancer. Journal of Gastrointestinal Surgery 2012, 16:104-12 (Epub Nov 4, 2011).
  • W. Qiu, F. Sahin, C.A. Iacobuzio-Donahue, Dario Garcia-Carracedo, W. M. Wang, Chia-Yu Kuo, Dan E. Arking, A. M. Lowy, R. H. Hruban, H. E. Remotti, G. H. Su. Disruption of p16 and Activation of Kras in Pancreas Increases Ductal Adenocarcinoma Formation and Metastasis in vivo.  Oncotarget 2011, 2:862-73 (Epub Nov 23, 2011).
  • W. Qiu and G. H. Su. Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer and Metastasis Review, 2013 (Epub Nov 1, 2012).
  • W. Qiu and G. H. Su. Development of orthotopic pancreatic tumor mouse models. Methods Mol Biol. 2013; 980:215-23.
  • R. D. Dinnen, Y. Mao, W. Qiu, N. Cassai, V. N. Slavkovich, G. Nichols, G. H. Su, P. Brandt-Rauf, R. L. Fine. Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. Molecular Cancer Therapeutics 2013; 12(12):2792-803. PMID: 24126434
  • D. Garcia-Carracedo, A. T. Turk, S. A. Fine, N. Akhavan, B. C. Tweel, R. Parsons, J. A. Chabot, J. D. Allendorf, J. M. Genkinger, H. E. Remotti, G. H. Su. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Research 2013, 19(24):6830-41. (Epub Nov 12, 2013). PMID: 24132918
  • W. Qiu, G. Tong, A. T. Turk, L. G. Close, S. M. Caruana, G. H. Su. Oncogenic PIK3CA is overexpressed and mutated in salivary duct carcinoma. BioMed Research International 2014; 810487. doi: 10.1155/2014/810487. (Epub Jan 8, 2014). PMID: 24511546
  • D. Garcia-Carracedo, Z. Chen, W. Qiu, A. S. Huang, S. M. Tang, R. H. Hruban, G. H. Su. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas, 2014; 43(2):245-9. PMID: 24518503
  • D. Garcia-Carracedo, C. C. Yu, N. Akhavan, S. A. Fine, F. Schönleben, N. Maehara, D. C. Karg, C. Xie, W. Qiu, R. L. Fine, H. E. Remotti, G. H. Su. Smad4 loss synergizes with TGFalpha overexpression in promoting metaplasia, PanIN development, and fibrosis. PLoS One 2015, Mar 24;10(3):e0120851.  PMCID: PMC4372593
  • J. Peng, P. T. Fullerton Jr., D. Monsivais, C. Clementi, G. H. Su, M. M. Matzuk. Uterine Activin-like Kinase 4 Regulates Trophoblast Development during Mouse Placentation. Molecular Endocrinology 2015; 29(12): 1684-93 (Epub Oct 20, 2015).
  • W. Qiu, S. M. Tang, S. Lee, A. T. Turk, A. N. Sireci, A. Qiu, C. Rose, C. Xie, J. Kitajewski, H.-J. Wen, H. C. Crawford, P. A. Sims, R. H. Hruban, H. E. Remotti, G. H. Su. Loss of Activin Receptor Type 1B Promotes Development of Intraductal Papillary Mucinous Neoplasms in Mice with Activated KRAS. Gastroenterology 2016; 150 (1)218-228 (Epub Sept 22, 2015).
  • C. B . Westphalen, Y. Takemoto, T. Tanaka, Macchini M, Z. Jiang, B. W. Renz, X. Chen, S. Ormanns, K. Nagar, Y. Tailor, R. May, Y. Cho, S. Asfaha, D. L. Worthley, Y. Hayakawa, A. M. Urbanska, M. Quante, M. Reichert, J. Broyde, P. S. Subramaniam, H. Remotti, G. H. Su, A. K. Rustgi, R. A. Friedman, B. Honig, A. Califano, C. W. Houchen, K. P. Olive, T. C. Wang. Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. Cell Stem Cell 2016; 18(4):441-55.
  • D. García-Carracedo, M. Ángeles Villaronga, S. Álvarez-Teijeiro, F. Hermida-Prado, I. Santamaría, E. Allonca, L. Suárez-Fernández, M. Victoria Gonzalez, M. Balbín, A. Astudillo, P. Martínez-Camblor, G. H. Su, J. Pablo Rodrigo, J. María García-Pedrero. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget 2016; 7(20):29780-93.
  • C. C. Yu, W. Qiu, C. S. Juang, M. M. Mansukhani, B. Halmos, G. H. Su. Mutant allele specific imbalance in oncogenes with copy number alterations: occurrence, mechanisms, and potential clinical implications. Cancer Letters 2016 (Accepted).